Medpace Inc.

While hundreds of millions around the world were celebrating the Lunar New Year of the wood dragon, a quiet shift and new reality was settling in in the Chinese biotech sector. The country's largest c

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Hasten Gets Greater China Rights T

There are a number of models for funding a private biotech company, but most involve going cap-in-hand to venture capital firms or other institutional investors and, after many meetings and much prese

While the fight against antimicrobial resistance often produces more lamentation than new products, some long-stalled therapies for the notoriously challenging bacteria Clostridium difficile have re